Coastlands Capital Acquires KTTA Shares
Coastlands Capital LP purchased 100,000 shares of KTTA at $0.53 per share.
Key Points
- Coastlands Capital LP bought 100,000 shares of KTTA at $0.53 each, totaling $53,000 on June 17, 2026.
- KTTA shares traded at $0.54 on Monday, with peer funds like Cable Car Capital increasing their holdings by 706,379 shares.
- Analysts from HC Wainwright & Co. reiterated a 'buy' rating for KTTA with a $3.00 price target on April 20, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Coastlands Capital LP bought 100,000 shares of KTTA at a price of $0.53 per share, making the total transaction worth $53,000. This purchase occurred on June 17, 2026, and was not part of a pre-planned trading scheme.
Other Institutional Activity in KTTA
Among KTTA's institutional investors, Cable Car Capital, LP significantly increased its stake by 706,379 shares, bringing its total to 1,206,379 shares valued at approximately $894,892. Meanwhile, Ameriprise Financial Inc reduced its holdings by 579,232 shares, ending with 1,350,896 shares worth about $1,002,094. Other notable investors like Vivo Capital, LLC and Janus Henderson Group PLC maintained their positions without changing their share counts.
Pasithea Therapeutics Corp. Stock Down 4.0%
Shares of KTTA traded around $0.54 on Monday. Although detailed financial metrics like market cap and P/E ratio aren't available, the stock's trading activity shows interest from various institutional investors. The 52-week range and moving averages were not provided, but the recent insider and institutional activities suggest ongoing engagement with the stock.
$KTTA stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Pasithea Therapeutics Corp.
In addition to Coastlands Capital's purchase, several other insiders made notable transactions. On May 1, 2026, Krishnan Kartik, the Chief Medical Officer, acquired 1,129,323 shares, while Tiago Marques, the CEO, bought 1,756,069 shares. These transactions were not part of any pre-arranged plans. Other insiders like Alfred Novak and Simon Dumesnil also made purchases on the same date.
Analysts Set New Price Targets
On April 20, 2026, HC Wainwright & Co. reiterated their 'buy' rating for KTTA and set a price target of $3.00. Earlier, on December 8, 2025, the same firm had initiated coverage with a similar rating and target. EF Hutton also initiated coverage with a 'buy' rating and a $2.00 target on June 1, 2023. The consensus outlook for KTTA remains positive with these ratings.
Bottom Line
Coastlands Capital's recent purchase of KTTA shares is part of a broader pattern of insider and institutional interest in the company. While the stock's current trading price is modest, analysts have set higher targets, suggesting potential upside. Investors often watch these insider activities as indicators of confidence in the company's future. However, it's important to remember that these trades are backward-looking and may not reflect current market conditions.
Get Pasithea Therapeutics Corp. alerts
New 13F filings, insider trades, and analyst moves on $KTTA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.